Savara Inc (SVRA) Stock
4 of the hedge funds AlphaScala tracks reported SVRA in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Marshall Wace's at $38.54M.
Which hedge funds own SVRA?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Marshall Wace | 6.26M | $38.54M | +39% |
| D.E. Shaw David Shaw | 2.51M | $15.49M | +19% |
| Citadel Ken Griffin | 261K | $1.61M | -67% |
| Renaissance Technologies Jim Simons (founder) | 249K | $1.53M | -62% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →SVRA price chart
Powered by TradingViewWhat does Savara Inc do?
Savara Inc. is a biopharmaceutical company focused on the development and commercialization of therapies for rare and chronic respiratory diseases. Dedicated to addressing unmet medical needs, Savara Inc. aims to bring innovative treatment options to patients with limited therapeutic choices. One of their primary developments includes inhalation therapies that cater to conditions such as pulmonary alveolar proteinosis, cystic fibrosis, and other lung-related diseases. By investing in targeted therapies, Savara Inc. plays a crucial role in the healthcare and biotechnology sectors, emphasizing its commitment to improving patient outcomes with specific attention to safety and efficacy. Operating within the niche of rare diseases, Savara Inc. holds a unique position in the biopharmaceutical market, contributing to advancements in respiratory health care. The company's strategies and research efforts are pivotal in driving forward the development of new treatment modalities for critical respiratory conditions, thereby marking its significance in both the medical community and the pharmaceutical industry.